According to Andrew Lowe, the U.S. government uses a value of a statistical life, most recently about $10 million, in policy decisions.
“In fact, the United States government, when they make policy decisions, they use a concept called the value of a statistical life. The most recent estimate is about $10 million.”
Freakonomics, M.D. · 0:10:53
According to Andrew Lowe, a U.S. patent on a new drug gives 20 years of exclusivity.
“You come up with a new drug, you get 20 years of exclusivity where you are the only person that can make use of that idea.”
Freakonomics, M.D. · 0:12:06
Andrew Lowe says FDA approval of a new drug generally takes about 5 to 15 years, depending on the disease.
“the FDA approval process generally takes on the order of 5 to 15 years, depending on the nature of the disease.”
Freakonomics, M.D. · 0:12:06
Andrew Lowe says a self-insured employer with about 1,000 plan members has an annual medical budget of about $6 million.
“With a thousand members of your plan, your annual budget is about $6 million.”
Freakonomics, M.D. · 0:13:03
Andrew Lowe says Goldman Sachs analyzed one-time cures and concluded drug companies have an incentive to develop chronic treatments rather than cures.
“In fact, a few years ago, Goldman Sachs looked at the economics of these one-time cures.”
Freakonomics, M.D. · 0:13:51
Gilead's originally proposed price for Sovaldi was $84,000, which Andrew Lowe calls a bargain from an economist's point of view.
“Gilead's original proposed market price was $84 ,000. And from an economist's point of view, that was a bargain.”
Freakonomics, M.D. · 0:18:29
Louisiana agreed to pay Gilead a fixed monthly amount per member, and Gilead agreed to treat all people in the state who needed the hepatitis C drug.
“the state of Louisiana developed an interesting approach. They agreed to pay Gilead a certain amount of money per member per month”
Freakonomics, M.D. · 0:18:29